Does HLA‐DQA1*05 carriage have a greater impact on the outcome of infliximab therapy for isolated small‐bowel Crohn's disease?
International Journal of Immunogenetics · 2024
DOI: 10.1111/iji.12696 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Immunogenetics, 2024. Verfasst von Juan Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Crohn Disease, HLA-DQ alpha-Chains, Infliximab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: 2023 Research Fund of Anhui Medical University, China.
Abstract (Originalsprache)
Carriage of HLA‐DQA1*05 is thought to increase the formation of anti‐tumour necrosis factor alpha (TNF‐α) antibodies, reducing the drug efficacy in Crohn's disease (CD) patients. However, little data are currently available for small‐bowel Crohn's disease (SB‐CD). A specific assessment of the impact of HLA‐DQA1*05 on the clinical response to treatment with infliximab (IFX), a TNF‐α antagonists, in SB‐CD patients is necessary. We conducted a single‐center retrospective study that included 106 SB‐CD patients treated with IFX. The serum samples were collected for antibodies to infliximab (ATI) testing and HLA‐DQA1*05 genotyping. Double‐balloon enteroscopy (DBE) was performed following the IFX treatment, with endoscopic outcomes evaluated using the partial simple endoscopic score for CD (pSES‐CD), whereas the clinical response was assessed with the Crohn's disease activity index (CDAI). Multivariate logistic regression and multivariate COX regression analyses were employed to analyze the correlation of the HLA‐DQA1*05 genotypes with other clinical variables. In this study, 30.2% of SB‐CD patients carried the HLA‐DQA1*05 allele, which significantly increased their risk of ATI generation (odds ratio [OR] = 2.337, p = .043), but it was not associated with the clinical response to IFX and drug persistence (OR = 2.356, p = .145; OR = 0.457, p = .249). The endoscopic remission rates were 40.6% (13/32) and 55.4% (41/74) in HLA‐DQA1*05 carriers and non‐carriers, respectively. HLA‐DQA1*05 was not associated with endoscopic remission (OR = 0.684, p = .414). The HLA‐DQA1*05 variant is identified as a significant risk factor of ATI formation in Chinese patients with SB‐CD, but is not associated with the clinical response of IFX treatment and endoscopic remission of SB lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- The First Clinical Medical College, Anhui Medical University, Hefei, China.
ORCID-Profile: Juan Wu, Qiao Mei, Bingqing Bai, Wei Han
Förderung
- 2023 Research Fund of Anhui Medical University, China
Zitieren
APA
Wu, J., Zhu, N., Hu, J., Zhang, C., Fang, Y., Wu, Y., Shi, Y., Liu, Q., Ding, H., Mei, Q., Bai, B., & Han, W. (2024). Does HLA‐DQA1*05 carriage have a greater impact on the outcome of infliximab therapy for isolated small‐bowel Crohn's disease?. International Journal of Immunogenetics. https://doi.org/10.1111/iji.12696
Vancouver
Wu J, Zhu N, Hu J, Zhang C, Fang Y, Wu Y, et al. Does HLA‐DQA1*05 carriage have a greater impact on the outcome of infliximab therapy for isolated small‐bowel Crohn's disease?. International Journal of Immunogenetics. 2024. doi:10.1111/iji.12696
BibTeX
@article{Wu2024,
author = {Wu, Juan and Zhu, Nannan and Hu, Jing and Zhang, Chenyu and Fang, Yuanyuan and Wu, Yumei and Shi, Yongrong and Liu, Qiuyuan and Ding, Hao and Mei, Qiao and Bai, Bingqing and Han, Wei},
title = {Does HLA‐DQA1*05 carriage have a greater impact on the outcome of infliximab therapy for isolated small‐bowel Crohn's disease?},
journal = {International Journal of Immunogenetics},
year = {2024},
doi = {10.1111/iji.12696}
}
EUVIMED